title: [The validation of the possible use of monosugars and 6-azacytidine for the elimination of Mollicutes associated with HIV/AIDS from the human urogenital tract].
abstract: A search for the methods new in principle which should block and eliminate AIDS-associated mycoplasmas was carried out. This work was conducted in two ways: 1) inhibition of vital activity of Mycoplasma fermentans PG-18 and Acholeplasma laidlawii PG-8 by 6-azacytidine; 2) establishment of carbohydrate composition of receptors for these mycoplasmas aimed at the competitive elimination of these microorganisms from urogenital tract of a man using carbohydrates. It is established that a 50%-inhibiting concentration of 6-azacytidine was 23.4 micrograms/ml for M. fermentans PG-18 and 62.5 micrograms/ml for A. laidlawii PG-8. alpha-D-glucose and N-acetylneuramine acid are two terminal carbohydrates that can serve as receptors for M. fermentans on human mucous membranes while D-mannose and N-acetyl-D-glucosamine for A. laidlawii PG-8. alpha-D-glucose in concentration 75 mM and N-acetylneuramine acid in concentration 150 mM competitively inhibit reception of M. fermentans on mucosae, while D-mannose in concentration 150 mM and N-acetyl-D-glucosamine in concentration 75 mM are antireceptor substances for A. laidlawii.
authors.forename: I H
authors.initials: IH
authors.lastname: Skrypal'
authors.forename: A M
authors.initials: AM
authors.lastname: Onyshchenko
authors.forename: I P
authors.initials: IP
authors.lastname: Tokovenko
authors.forename: L P
authors.initials: LP
authors.lastname: Malynovs'ka
authors.forename: L P
authors.initials: LP
authors.lastname: Panchenko
authors.forename: L O
authors.initials: LO
authors.lastname: Havrylko
authors.forename: A S
authors.initials: AS
authors.lastname: Shalamaĭ
authors.forename: I V
authors.initials: IV
authors.lastname: Aleksieieva
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000378:metabolism / Q000382:microbiology*; D000128:Acholeplasma laidlawii / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000494:pharmacology*; D001374:Azacitidine / Q000031:analogs & derivatives* / Q000494:pharmacology; D001667:Binding, Competitive / Q000187:drug effects; D003470:Culture Media; D015497:HIV-1; D006801:Humans; D009005:Monosaccharides / Q000378:metabolism / Q000494:pharmacology*; D009175:Mycoplasma Infections / Q000378:metabolism / Q000382:microbiology*; D016858:Mycoplasma fermentans / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D011956:Receptors, Cell Surface / Q000187:drug effects / Q000378:metabolism; D014566:Urogenital System / Q000378:metabolism / Q000382:microbiology*
chemical_list: D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D003470:Culture Media; D009005:Monosaccharides; D011956:Receptors, Cell Surface; D001374:Azacitidine; C040881:6-azacytidine
vernacular_title: Obhruntuvannia mozhlyvosti zastosuvannia monotsukriv i 6-azatsytydynu dlia eliminatsiï z urohenital'noho traktu liudyny molikutiv, iaki asotsiiuiut' z VIL/SNIDom.